{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:27:34Z","timestamp":1791469654686,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015682","name":"INCLIVA Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015682","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018689","name":"Spanish Clinical Research Network","doi-asserted-by":"publisher","award":["SCReN; PT17\/0017\/0003 y PT20\/00100"],"award-info":[{"award-number":["SCReN; PT17\/0017\/0003 y PT20\/00100"]}],"id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"CIBER","doi-asserted-by":"publisher","award":["16\/11\/00420"],"award-info":[{"award-number":["16\/11\/00420"]}],"id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"CIBER","doi-asserted-by":"publisher","award":["16\/11\/00403"],"award-info":[{"award-number":["16\/11\/00403"]}],"id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Heart Fail"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to evaluate the effect of dapagliflozin on 1 and 3\u2010month maximal functional capacity in patients with stable heart failure with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      In this multicentre, randomized, double\u2010blind clinical trial, 90 stable patients with HFrEF were randomly assigned to receive either dapagliflozin (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a045) or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a045). The primary outcome was a change in peak oxygen consumption (peakVO\n                      <jats:sub>2<\/jats:sub>\n                      ) at 1 and 3\u2009months. Secondary endpoints were changes at 1 and 3\u2009months in 6\u2010min walk test (6MWT) distance, quality of life (Minnesota Living with Heart Failure Questionnaire [MLHFQ]), and echocardiographic parameters (diastolic function, left chamber volumes, and left ventricular ejection fraction). We used linear mixed regression analysis to compare endpoint changes. Estimates were adjusted for multiple comparisons. The mean age was 67.1\u2009\u00b1\u200910.7\u2009years, 69 (76.7%) were men, 29 (32.2%) had type 2 diabetes, and 80 (88.9%) were in New York Heart Association class II. Baseline means of peakVO\n                      <jats:sub>2<\/jats:sub>\n                      , 6MWT and MLHFQ were 13.2\u2009\u00b1\u20093.5\u00a0ml\/kg\/min, 363\u2009\u00b1\u2009110\u2009m, and 23.1\u2009\u00b1\u200916.2, respectively. The median (25th\u201375th percentile) of N\n                      <jats:italic>\u2010<\/jats:italic>\n                      terminal pro\u2010brain natriuretic peptide was 1221\u2009pg\/ml (889\u20132100). Most patients were on treatment with sacubitril\/valsartan (88.9%), beta\u2010blockers (91.1%), and mineralocorticoid receptor antagonists (74.4%). PeakVO\n                      <jats:sub>2<\/jats:sub>\n                      significantly increased in patients on treatment with dapagliflozin (1\u2009month: +\u0394 1.09\u2009ml\/kg\/min, 95% confidence interval [CI] 0.14\u20132.04;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.021, and 3\u2009months: +\u0394 1.06\u2009ml\/kg\/min, 95% CI 0.07\u20132.04;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.032). Similar positive findings were found when evaluating changes from baseline. No significant differences were observed in secondary endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Among patients with stable HFrEF, dapagliflozin resulted in a significant improvement in peakVO\n                      <jats:sub>2<\/jats:sub>\n                      at 1 and 3\u2009months.\n                    <\/jats:p>\n                    <jats:p>\n                      Clinical Trial Registration:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      Identifier: NCT04197635.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2560","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T10:58:33Z","timestamp":1653303513000},"page":"1816-1826","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Short\u2010term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (\n                    <scp>\n                      DAPA\u2010VO\n                      <sub>2<\/sub>\n                    <\/scp>\n                    ): a randomized clinical trial"],"prefix":"10.1093","volume":"24","author":[{"given":"Patricia","family":"Palau","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Amiguet","sequence":"additional","affiliation":[{"name":"Fisabio Universitat Jaume I  Castell\u00f3n Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloy","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Fisabio Universitat Jaume I  Castell\u00f3n Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sastre","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mollar","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Seller","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital de Denia  Alicante Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Garcia Pinilla","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital Universitario Virgen de la Victoria, IBIMA  M\u00e1laga Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainoha","family":"Larumbe","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital de Denia  Alicante Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Valle","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital de Denia  Alicante Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"G\u00f3mez Doblas","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital Universitario Virgen de la Victoria, IBIMA  M\u00e1laga Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Espriella","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa Robles","family":"Mezcua","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital Universitario Virgen de la Victoria, IBIMA  M\u00e1laga Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Santas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicent","family":"Bod\u00ed","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sanchis","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Pascual\u2010Figal","sequence":"additional","affiliation":[{"name":"Cardiology Department Hospital Universitario Virgen de la Arrixaca  Murcia Spain"},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[{"name":"Nephrology Department Hospital Cl\u00ednico Universitario de Valencia, Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ba\u00fdes\u2010Gen\u00eds","sequence":"additional","affiliation":[{"name":"CIBER Cardiovascular  Madrid Spain"},{"name":"Department and Heart Failure Unit Hospital Universitari Germans Trias i Pujol  Badalona Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia Universitat de Val\u00e8ncia, INCLIVA  Valencia Spain"},{"name":"CIBER Cardiovascular  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DAPA\u2010VO Investigators (see Appendix)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","journal-title":"Circulation"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2333"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.7585"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jex244"},{"key":"e_1_2_8_9_1","unstructured":"US Food and Drug Administration.Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. June 2019.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/treatment\u2010heart\u2010failure\u2010endpoints\u2010drug\u2010development\u2010guidance\u2010industry[accessed 23 May 2022]."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.979"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2355"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020262"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2017.11.019"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1838"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.008"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22899"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045691"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1713"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1096"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.06.045"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.07.010"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:16:03Z","timestamp":1767701763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejhf.2560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/ejhf.2560"],"URL":"https:\/\/doi.org\/10.1002\/ejhf.2560","archive":["Portico"],"relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"2022-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}